A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 206
- Registration Number
- NCT05911360
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 94
- Registration Number
- NCT05896748
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 118
- Registration Number
- NCT05896761
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT05776108
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
Phase 1
Recruiting
- Conditions
- HIV Infections
- Interventions
- Drug: Dolutegravir/Rilpivirine FDC
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT05674656
- Locations
- πΊπΈ
GSK Investigational Site, Houston, Texas, United States
A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 105
- Registration Number
- NCT05631704
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories
Phase 4
Active, not recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 66
- Registration Number
- NCT05514509
- Locations
- πΊπΈ
GSK Investigational Site, Norfolk, Virginia, United States
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 180
- Registration Number
- NCT05418868
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 73
- Registration Number
- NCT05393271
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 201
- Registration Number
- NCT05374525
- Locations
- πΊπΈ
GSK Investigational Site, Seattle, Washington, United States
Β© Copyright 2025. All Rights Reserved by MedPath